About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker VIR · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination…
NCT05356741 · Locally Advanced or Metastatic HER2-Expressing Cancers
VIR-5818, pembrolizumab
VIR
Vir Biotechnology, Inc.
Phase 1/2Recruiting645Apr 2028Registry ↗
Nov 3, 2026A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
NCT06903338 · Viral Hepatitis
Tobevibart, Elebsiran
VIR
Vir Biotechnology, Inc.
Phase 3Active, not recruiting124Sep 30, 2026Registry ↗
Oct 16, 2026A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
NCT05844228 · Renal Impairment
VIR-2218
VIR
Vir Biotechnology, Inc.
Phase 1Completed28Mar 1, 2025Registry ↗
Sep 9, 2026Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
NCT05484206 · Hepatic Impairment, Cirrhosis
VIR-2218, VIR-3434
VIR
Vir Biotechnology, Inc.
Phase 1Completed88Dec 9, 2025Registry ↗
Jul 13, 2026A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virological…
NCT07128550 · Viral Hepatitis
Tobevibart, Elebsiran
VIR
Vir Biotechnology, Inc.
Phase 3Active, not recruiting150Dec 2026Registry ↗
Jun 26, 2026SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
NCT05461170 · Hepatitis D, Chronic
VIR-2218, VIR-3434
VIR
Vir Biotechnology, Inc.
Phase 2Active, not recruiting95Nov 2031Registry ↗
Apr 23, 2026Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
NCT04856085 · Hepatitis B, Chronic
VIR-2218, VIR-3434
VIR
Vir Biotechnology, Inc.
Phase 2Completed244Mar 16, 2026Registry ↗
Apr 16, 2026Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis…
NCT04412863 · Chronic Hepatitis B
VIR-2218, pegylated interferon-alfa 2a
VIR
Vir Biotechnology, Inc.
Phase 2Completed84Mar 25, 2024Registry ↗
Apr 13, 2026Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Local…
NCT06960395 · Solid Tumor Malignancies, EGFR Positive Solid Tumors
VIR-5525, Pembrolizumab
VIR
Vir Biotechnology, Inc.
Phase 1Recruiting450Aug 2029Registry ↗
Feb 9, 2026A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
NCT05612581 · Hepatitis B, Chronic
VIR-3434, VIR-2218
VIR
Vir Biotechnology, Inc.
Phase 1/2Completed33Oct 15, 2024Registry ↗
Jan 16, 2026A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
NCT07142811 · Viral Hepatitis
Tobevibart, Elebsiran
VIR
Vir Biotechnology, Inc.
Phase 2Active, not recruiting100Nov 2026Registry ↗
Oct 8, 2024Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
NCT04423393 · Chronic Hepatitis B
VIR-3434, Placebo
VIR
Vir Biotechnology, Inc.
Phase 1Completed113Oct 24, 2022Registry ↗
Sep 19, 2024A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due t…
NCT05567783 · Influenza A
VIR-2482 (450 mg), VIR-2482 (1200 mg)
VIR
Vir Biotechnology, Inc.
Phase 2Terminated2,977May 5, 2023Registry ↗
Sep 19, 2024Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (C…
NCT05280717 · Covid19
sotrovimab, sotrovimab
VIR
Vir Biotechnology, Inc.
Phase 1Terminated316Apr 5, 2023Registry ↗
Jun 7, 2024A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or…
NCT04988152 · Covid19
sotrovimab, Placebo to Biologic
VIR
Vir Biotechnology, Inc.
Phase 1Completed48Sep 2, 2021Registry ↗
Mar 7, 2024Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.
NCT04913675 · Covid19
sotrovimab, sotrovimab
VIR
Vir Biotechnology, Inc.
Phase 3Terminated1,065Jul 19, 2022Registry ↗
May 3, 2023Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalize…
NCT04779879 · Covid19
Sotrovimab (Gen1), Sotrovimab (Gen2)
VIR
Vir Biotechnology, Inc.
Phase 2Completed354Aug 20, 2021Registry ↗
Feb 27, 2023VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Vol…
NCT04725877 · HIV I Infection
VIR-1111, Placebo
VIR
Vir Biotechnology, Inc.
Phase 1Completed27Dec 5, 2022Registry ↗
Nov 10, 2022Sotrovimab Expanded Access Treatment Protocol (COVID-19)
NCT05235347 · Covid19
Sotrovimab
VIR
Vir Biotechnology, Inc.
—No longer available——Registry ↗
Nov 7, 2022VIR-7831 for the Early Treatment of COVID-19 in Outpatients
NCT04545060 · Covid19
VIR-7831 (sotrovimab), Placebo
VIR
Vir Biotechnology, Inc.
Phase 2/3Completed1,057Apr 8, 2021Registry ↗
Jun 9, 2022Study of VIR-2482 in Healthy Volunteers
NCT04033406 · Influenza A
VIR-2482, Placebo
VIR
Vir Biotechnology, Inc.
Phase 1Completed100Nov 1, 2021Registry ↗
Dec 13, 2021Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
NCT03672188 · Chronic Hepatitis B
VIR-2218, Placebo
VIR
Vir Biotechnology, Inc.
Phase 1/2Completed82Sep 3, 2020Registry ↗

22 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:44 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances